Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers

Inclusion Criteria: * Diagnosis of type 1 or 2 diabetes mellitus * Target diabetic foot ulcer with a minimum surface area of 1.0 cm\^2 and a maximum surface area of 20.0 cm\^2 measured post-debridement with photographic planimetry. * Target ulcer must have been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care prior to initial screening * Target ulcer must be located on the foot with at least 50% of its area below the malleolus * Target ulcer must be full thickness on the foot or ankle that does not probe to bone * Adequate circulation in the affected foot documented within 3 months of initial screening visit, as determined by one of the following: transcutaneous oximetry measurement (TCOM) greater or equal to 30 mmHg, ankle-brachial index (ABI) between 0.7 and 1.3, biphasic pulse volume recording (PVR), toe-brachial index (TBI) greater than 0.6, or arterial Doppler ultrasound evaluating for biphasic dorsalis pedis and posterior tibial vessels at the ankle level * If subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer * Target ulcers on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization * Subject must consent to using the prescribed off-loading method for the duration of the study * Subject must agree to attend weekly study visits required by the protocol * Subject must be willing and able to participate in the informed consent process Exclusion Criteria: * Subjects known to have a life expectancy of \< 6 months * Infection of the target ulcer or cellulitis in the surrounding skin * Presence of osteomyelitis or exposed bone, or wounds that probe to bone or joint capsule on investigator's exam or radiographic evidence * Infection in the target ulcer requiring systemic antibiotic therapy * Subjects receiving immunosuppressants (including systemic corticosteroids \> 10 mg Prednisone per day or equivalent) or cytotoxic chemotherapy * Topical application of steroids to the ulcer surface within one month of initial screening * Subjects with previous partial amputation on the affected foot that impedes proper offloading of the target ulcer * Subjects with a glycated hemoglobin (HbA1c) greater than or equal to 13% taken at or within 3 months of the initial screening visit * Subjects with a serum creatinine level ≥ 3.0mg/dL within 6 months of randomization * Surface area of the target ulcer reduces in size by more than 30% in the two weeks between the initial screening and randomization during which they are subject to standard of care * Subjects with acute or inactive Charcot foot that impedes proper offloading of the target ulcer * Women who are pregnant or considering becoming pregnant within the next 6 months * Subjects with end stage renal disease requiring dialysis * Subjects who participated in a clinical trial involving treatment with an investigational product within the previous 30 days * Subjects who, in the opinion of the investigator, have a medical or psychological condition that may interfere with study assessments * Subjects treated with hyperbaric oxygen therapy or a cellular and/or tissue product (CTP) in the 30 days prior to the initial screening visit